May 2 (Reuters) - HistoSonics, a medical technology company backed by Johnson & Johnson JNJ.N, is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.
The company is seeking a valuation of more than $2.5 billion, the report said.
(Reporting by Bipasha Dey in Bengaluru; Editing by Sonia Cheema)
((Bipasha.Dey@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.